China Biologic Products (CBPO) Reports Q1 EPS of $1.56

China Biologic Products (NASDAQ: CBPO) reported Q1 EPS of $1.56, versus $1.11 reported last year. Revenue for the quarter came in at $162.6 million, versus $129.8 million reported last year.

Financial Outlook

The COVID-19 outbreak has impacted various aspects of CBPO's operations, including plasma collection, production of certain products, and sales and marketing activities. The Company continues to actively evaluate the overall impact of the outbreak on its business and will provide financial guidance for the full year 2020 when it has better visibility.

For earnings history and earnings-related data on China Biologic Products (CBPO) click here.

You May Also Be Interested In

• Some Said Inflation Risks Had Become More Skewed To Upside - FOMC Minutes
• Levi Strauss beats profit forecasts, shares edge higher
• Oaktree exits TORM stake via 6.3 million share secondary offering